ReNerve Limited (ASX:RNV)
Australia · Delayed Price · Currency is AUD 0.0900
0.00 (0.00%)
Oct 28, 2026, 3:43 PM AEDT
ReNerve Revenue
In the fiscal year ending June 30, 2026, ReNerve had annual revenue of 510.36K AUD with 87.83% growth. ReNerve had revenue of 346.64K in the half year ending June 30, 2026, with 149.28% growth. That makes ReNerve the 44,881st largest company in the world by revenue and 1,089th in Australia.
Revenue
510.36K
Revenue Growth
+87.83%
P/S Ratio
30.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.51M
Revenue by Geography
- United States 508.05K 99.5%
- New Zealand 2.31K 0.5%
Fiscal year ended Jun 30, 2026 See the full ReNerve breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 510.36K | 238.65K | 87.83% |
| Jun 30, 2025 | 271.71K | 94.33K | 53.18% |
| Jun 30, 2024 | 177.37K | 48.88K | 38.04% |
| Jun 30, 2023 | 128.49K | - | - |
| Jun 30, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Radiopharm Theranostics | 12.87M |
| Immuron | 7.71M |
| Argenica Therapeutics | 5.48M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |
| Cambium Bio | 1.23M |